GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Revenio Group Oyj (OTCPK:REVXF) » Definitions » EV-to-EBIT

Revenio Group Oyj (Revenio Group Oyj) EV-to-EBIT : 27.91 (As of May. 12, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Revenio Group Oyj EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Revenio Group Oyj's Enterprise Value is $761.9 Mil. Revenio Group Oyj's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $27.3 Mil. Therefore, Revenio Group Oyj's EV-to-EBIT for today is 27.91.

The historical rank and industry rank for Revenio Group Oyj's EV-to-EBIT or its related term are showing as below:

REVXF' s EV-to-EBIT Range Over the Past 10 Years
Min: 14.03   Med: 34.87   Max: 95.6
Current: 28.03

During the past 13 years, the highest EV-to-EBIT of Revenio Group Oyj was 95.60. The lowest was 14.03. And the median was 34.87.

REVXF's EV-to-EBIT is ranked worse than
64.84% of 455 companies
in the Medical Devices & Instruments industry
Industry Median: 20.82 vs REVXF: 28.03

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Revenio Group Oyj's Enterprise Value for the quarter that ended in Mar. 2024 was $731.7 Mil. Revenio Group Oyj's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $27.3 Mil. Revenio Group Oyj's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 3.73%.


Revenio Group Oyj EV-to-EBIT Historical Data

The historical data trend for Revenio Group Oyj's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revenio Group Oyj EV-to-EBIT Chart

Revenio Group Oyj Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 55.87 78.60 66.07 34.59 27.54

Revenio Group Oyj Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.50 30.01 20.24 27.54 26.09

Competitive Comparison of Revenio Group Oyj's EV-to-EBIT

For the Medical Devices subindustry, Revenio Group Oyj's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revenio Group Oyj's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Revenio Group Oyj's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Revenio Group Oyj's EV-to-EBIT falls into.



Revenio Group Oyj EV-to-EBIT Calculation

Revenio Group Oyj's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=761.859/27.296
=27.91

Revenio Group Oyj's current Enterprise Value is $761.9 Mil.
Revenio Group Oyj's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $27.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revenio Group Oyj  (OTCPK:REVXF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Revenio Group Oyj's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=27.296/731.73188
=3.73 %

Revenio Group Oyj's Enterprise Value for the quarter that ended in Mar. 2024 was $731.7 Mil.
Revenio Group Oyj's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $27.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Revenio Group Oyj EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Revenio Group Oyj's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Revenio Group Oyj (Revenio Group Oyj) Business Description

Traded in Other Exchanges
Address
Ayritie 22, Vantaa, FIN, 01510
Revenio Group Oyj is a Finnish health technology company. It develops and commercializes effective and easy-to-use health tech-related screening devices for the detection of diseases of significance to public health. Its ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), perimeter and fundus imaging devices under the iCare brand. Its eye care software platform Oculo offers clinical communication, telehealth, remote patient monitoring, and data analytics capabilities. The company's geographical segments include Finland, Other Europe, and Others.

Revenio Group Oyj (Revenio Group Oyj) Headlines

From GuruFocus

Q4 2023 Revenio Group Oyj Earnings Call Transcript

By GuruFocus Research 02-28-2024